Cargando…
Body mass index, as a novel predictor of hepatocellular carcinoma patients treated with Anti-PD-1 immunotherapy
Immunocheckpoint inhibitors have shown significant efficacy in the treatment of hepatocellular carcinoma (HCC), but there are individual differences. The aim of this study was to explore body mass index (BMI) as a predictor of anti-PD-1 efficacy in patients with HCC. We retrospectively analyzed 101...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530364/ https://www.ncbi.nlm.nih.gov/pubmed/36203764 http://dx.doi.org/10.3389/fmed.2022.981001 |
_version_ | 1784801666583756800 |
---|---|
author | Chen, Jierong Lu, Lianghe Qu, Chunhua A, Gari Deng, Fangqi Cai, Muyan Chen, Wei Zheng, Lie Chen, Jiewei |
author_facet | Chen, Jierong Lu, Lianghe Qu, Chunhua A, Gari Deng, Fangqi Cai, Muyan Chen, Wei Zheng, Lie Chen, Jiewei |
author_sort | Chen, Jierong |
collection | PubMed |
description | Immunocheckpoint inhibitors have shown significant efficacy in the treatment of hepatocellular carcinoma (HCC), but there are individual differences. The aim of this study was to explore body mass index (BMI) as a predictor of anti-PD-1 efficacy in patients with HCC. We retrospectively analyzed 101 HCC patients who treated with anti-PD-1 at Sun Yat-sen University Cancer Center from July 2018 to November 2019 and divided them into overweight (BMI > 24.9) and non-overweight (BMI ≤ 24.9) groups based on baseline BMI levels. BMI > 24.9 accounted for 22 cases (21.8%) and BMI ≤ 24.9 accounted for 79 cases (78.2%) in the study cohort. Overweight patients had higher disease control rates than non-overweight patients (P = 0.019, respectively). The mean progression-free survival (PFS) in overweight patients (10.23 months) was significantly longer than that of non-overweight patients (6.85 months; P = 0.027). Among patients with immune-related adverse events (irAEs), the mean PFS was also significantly longer in overweight patients (7.72 months) than in non-overweight patients (5.31 months, P = 0.034). Multivariate analysis showed that BMI was an independent prognostic factor for PFS in HCC patients treated with anti-PD-1 (hazard ratio: 0.47, P = 0.044). Thus, higher BMI predicts a better prognosis among HCC patients treated with anti-PD-1. In clinical practice, patients' BMI can provide a useful tool for predicting the efficacy of anti-PD-1 therapy. |
format | Online Article Text |
id | pubmed-9530364 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95303642022-10-05 Body mass index, as a novel predictor of hepatocellular carcinoma patients treated with Anti-PD-1 immunotherapy Chen, Jierong Lu, Lianghe Qu, Chunhua A, Gari Deng, Fangqi Cai, Muyan Chen, Wei Zheng, Lie Chen, Jiewei Front Med (Lausanne) Medicine Immunocheckpoint inhibitors have shown significant efficacy in the treatment of hepatocellular carcinoma (HCC), but there are individual differences. The aim of this study was to explore body mass index (BMI) as a predictor of anti-PD-1 efficacy in patients with HCC. We retrospectively analyzed 101 HCC patients who treated with anti-PD-1 at Sun Yat-sen University Cancer Center from July 2018 to November 2019 and divided them into overweight (BMI > 24.9) and non-overweight (BMI ≤ 24.9) groups based on baseline BMI levels. BMI > 24.9 accounted for 22 cases (21.8%) and BMI ≤ 24.9 accounted for 79 cases (78.2%) in the study cohort. Overweight patients had higher disease control rates than non-overweight patients (P = 0.019, respectively). The mean progression-free survival (PFS) in overweight patients (10.23 months) was significantly longer than that of non-overweight patients (6.85 months; P = 0.027). Among patients with immune-related adverse events (irAEs), the mean PFS was also significantly longer in overweight patients (7.72 months) than in non-overweight patients (5.31 months, P = 0.034). Multivariate analysis showed that BMI was an independent prognostic factor for PFS in HCC patients treated with anti-PD-1 (hazard ratio: 0.47, P = 0.044). Thus, higher BMI predicts a better prognosis among HCC patients treated with anti-PD-1. In clinical practice, patients' BMI can provide a useful tool for predicting the efficacy of anti-PD-1 therapy. Frontiers Media S.A. 2022-09-20 /pmc/articles/PMC9530364/ /pubmed/36203764 http://dx.doi.org/10.3389/fmed.2022.981001 Text en Copyright © 2022 Chen, Lu, Qu, A, Deng, Cai, Chen, Zheng and Chen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Chen, Jierong Lu, Lianghe Qu, Chunhua A, Gari Deng, Fangqi Cai, Muyan Chen, Wei Zheng, Lie Chen, Jiewei Body mass index, as a novel predictor of hepatocellular carcinoma patients treated with Anti-PD-1 immunotherapy |
title | Body mass index, as a novel predictor of hepatocellular carcinoma patients treated with Anti-PD-1 immunotherapy |
title_full | Body mass index, as a novel predictor of hepatocellular carcinoma patients treated with Anti-PD-1 immunotherapy |
title_fullStr | Body mass index, as a novel predictor of hepatocellular carcinoma patients treated with Anti-PD-1 immunotherapy |
title_full_unstemmed | Body mass index, as a novel predictor of hepatocellular carcinoma patients treated with Anti-PD-1 immunotherapy |
title_short | Body mass index, as a novel predictor of hepatocellular carcinoma patients treated with Anti-PD-1 immunotherapy |
title_sort | body mass index, as a novel predictor of hepatocellular carcinoma patients treated with anti-pd-1 immunotherapy |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530364/ https://www.ncbi.nlm.nih.gov/pubmed/36203764 http://dx.doi.org/10.3389/fmed.2022.981001 |
work_keys_str_mv | AT chenjierong bodymassindexasanovelpredictorofhepatocellularcarcinomapatientstreatedwithantipd1immunotherapy AT lulianghe bodymassindexasanovelpredictorofhepatocellularcarcinomapatientstreatedwithantipd1immunotherapy AT quchunhua bodymassindexasanovelpredictorofhepatocellularcarcinomapatientstreatedwithantipd1immunotherapy AT agari bodymassindexasanovelpredictorofhepatocellularcarcinomapatientstreatedwithantipd1immunotherapy AT dengfangqi bodymassindexasanovelpredictorofhepatocellularcarcinomapatientstreatedwithantipd1immunotherapy AT caimuyan bodymassindexasanovelpredictorofhepatocellularcarcinomapatientstreatedwithantipd1immunotherapy AT chenwei bodymassindexasanovelpredictorofhepatocellularcarcinomapatientstreatedwithantipd1immunotherapy AT zhenglie bodymassindexasanovelpredictorofhepatocellularcarcinomapatientstreatedwithantipd1immunotherapy AT chenjiewei bodymassindexasanovelpredictorofhepatocellularcarcinomapatientstreatedwithantipd1immunotherapy |